BioCentury
ARTICLE | Financial News

ObsEva raises $34.6 million in series A

August 29, 2013 11:21 PM UTC

Reproductive health company ObsEva S.A. (Geneva, Switzerland) raised CHF32 million ($34.6 million) in a series A round co-led by Sofinnova Partners; Sofinnova Ventures; and Novo A/S. Additionally, the Merck Serono division of Merck KGaA (Xetra:MRK) granted ObsEva exclusive, worldwide rights to undisclosed compounds to prevent preterm labor. ObsEva said the lead compound has completed Phase I testing, with Phase II testing slated to start next year. As part of the deal, Merck Serono's corporate VC arm, MS Ventures, received a minority equity stake in ObsEva. ...